Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molibresib + Fulvestrant in HR+/HER2- Breast Cancer
NCT02964507Phase 1Terminated
- Sponsor
- GSK
- Start
- Sep 2019
- Primary completion
- Sep 2020
- Modality
- Allosteric Modulators
- Countries
- 7
01
Overview
Phase 1, randomised, double-blind trial of molibresib in Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative) (3 arms), sponsored by GSK. Primary endpoints: Number of Participants With Non-serious Adverse Events and Serious Adverse Events, Number of Participants With Dose Limiting Toxicities up to 28 days and 4 more. Started Sep 2019; status: terminated.
02
Drugs
molibresib
03
Conditions
Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative)
Beyond the preview
Go deeper on NCT02964507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964507.